HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.
The amino acid at position 36 of the HIV-1 protease differs among various viral subtypes, in that methionine is usually found in subtype B viruses but isoleucine is common in other subtypes. This polymorphism is associated with higher rates of treatment failure involving protease inhibitors (PIs) in non-subtype B-infected patients. To investigate this, we generated genetically homogeneous wild-type viruses from subtype B, subtype C, and CRF02_AG full-length molecular clones and showed that subtype C and CRF02_AG I36 viruses exhibited higher levels of resistance to various PIs than their respective M36 counterparts, while the opposite was observed for subtype B viruses. Selections for resistance with each variant were performed with nelfinavir (NFV), lopinavir (LPV), and atazanavir (ATV). Sequence analysis of the protease gene at week 35 revealed that the major NFV resistance mutation D30N emerged in NFV-selected subtype B viruses and in I36 subtype C viruses, despite polymorphic variation. A unique mutational pattern developed in subtype C M36 viruses selected with NFV or ATV. The presence of I47A in LPV-selected I36 CRF02_AG virus conferred higher-level resistance than L76V in LPV-selected M36 CRF02_AG virus. Phenotypic analysis revealed a >1,000-fold increase in NFV resistance in I36 subtype C NFV-selected virus with no apparent impact on viral replication capacity. Thus, the position 36 polymorphism in the HIV-1 protease appears to have a differential effect on both drug susceptibility and the viral replication capacity, depending on both the viral subtype and the drug being evaluated.
Lisovsky
Irene
I
McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
Schader
Susan M
SM
Martinez-Cajas
Jorge-Luis
JL
Oliveira
Maureen
M
Moisi
Daniela
D
Wainberg
Mark A
MA
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D002460:Cell Line; D002478:Cells, Cultured; D003062:Codon / Q000235:genetics*; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology* / Q000502:physiology; D006801:Humans; D061466:Lopinavir; D019888:Nelfinavir / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000235:genetics*; D011725:Pyridines / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use
D019380:Anti-HIV Agents; D003062:Codon; D009842:Oligopeptides; D011725:Pyridines; D011744:Pyrimidinones; D061466:Lopinavir; D000069446:Atazanavir Sulfate; D016333:HIV Protease; C514803:p16 protease, Human immunodeficiency virus 1; D019888:Nelfinavir
AIDS. 2006 Oct 24;20(16):W13-23
17053344
Antimicrob Agents Chemother. 2006 Jun;50(6):2210-3
16723586
Antimicrob Agents Chemother. 2006 Feb;50(2):694-701
16436728
N Engl J Med. 2004 Mar 4;350(10):1023-35
14999114
AIDS. 2004 Apr 9;18(6):909-15
15060438
AIDS Rev. 2003 Jul-Sep;5(3):165-71
14598565
J Virol. 1997 Sep;71(9):6662-70
9261388
Antimicrob Agents Chemother. 2004 Jun;48(6):2159-65
15155216
Trop Med Int Health. 2008 Feb;13(2):144-51
18304259
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6062-7
11353856
J Virol. 1996 Jun;70(6):3763-9
8648711
N Engl J Med. 2008 Apr 10;358(15):1590-602
18403767
PLoS Med. 2005 Apr;2(4):e112
15839752
AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1083-7
11485626
J Clin Virol. 2006 Aug;36(4):264-71
16765636
Pediatr Infect Dis J. 2005 Dec;24(12):1072-6
16371868
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
12019106
Antiviral Res. 2007 Dec;76(3):203-21
17673305
Nat Rev Microbiol. 2007 Feb;5(2):141-51
17203103
Antimicrob Agents Chemother. 2005 May;49(5):1739-44
15855490
J Mol Biol. 2007 Jul 13;370(3):598-607
17524421
AIDS Rev. 2008 Oct-Dec;10(4):212-23
19092977
J Virol. 1998 Apr;72(4):2855-64
9525605
J Virol. 2002 Aug;76(15):7398-406
12097552
J Virol. 1986 Aug;59(2):284-91
3016298
AIDS Res Hum Retroviruses. 1999 Sep 20;15(14):1321-4
10505681
Science. 2000 Apr 7;288(5463):55-6
10766634
J Clin Microbiol. 1994 Aug;32(8):2000-2
7527427
Antiviral Res. 2002 Nov;56(2):129-42
12367719
J Infect Dis. 2004 Jun 1;189(11):1983-7
15143463
J Virol. 2001 Aug;75(16):7462-9
11462018
J Virol. 2007 Oct;81(19):10209-19
17634242
AIDS. 2006 Mar 21;20(5):643-51
16514293
Biochemistry. 2003 Dec 30;42(51):15029-35
14690411
Structure. 2005 Dec;13(12):1887-95
16338417
Curr Drug Metab. 2004 Aug;5(4):321-8
15320704
Br Med Bull. 2001;58:19-42
11714622
AIDS. 2003 Jan 3;17(1):F1-5
12478089